Aerocrine provides update on its first quarter sales

Aerocrine provides update on its first quarter sales

SOLNA, Sweden - 7 April 2010 - Aerocrine AB today announced that its first
quarter sales development has been below expectations. Revenues are estimated to
reach approximately 18 MSEK compared to 26,9 MSEK previous year.

Following a strong sales performance in the first quarter of 2009, Aerocrine
estimates that sales in the first quarter of 2010 will be lower than the
previous year and reach approximately 18 MSEK.  Sales have been negatively
affected by a combination of several factors.  Heavy restrictions on healthcare
expenditures have been imposed in a number of key countries, partly due to
unbudgeted expenses for flue vaccinations last autumn.  The company's sales
growth is sensitive to healthcare budget priorities pending inclusion in
clinical guidelines and full reimbursement supporting the critical importance of
inflammation monitoring in the management of asthma.  Sales in December last
year was particularly strong, affecting the start of this year.  Price
competition is also emerging in a limited number of countries where smaller
competing suppliers offer low prices to larger customers.  Finally, Aerocrine
has been through a period of intense legal proceedings which has consumed
considerable time and organizational focus.

“While gross margins and control of operational costs have been maintained, our
sales performance in the first quarter has been disappointing.  However, our
sales pipeline is encouraging and we feel confident that we will bring the
company back to sales growth going forward,” said Paul de Potocki, CEO of
Aerocrine AB.  “Also, the recent developments of our U.S. and German patent
litigations as a result of Apieron Inc. filing for bankruptcy will allow us to
focus fully on sales promoting activities in the U.S.”

Aerocrine will issue its full first quarter financial report on 27 April.

For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 80

About Aerocrine
Aerocrine AB is a medical technology company focused on the improved management
and care of patients with inflammatory airway diseases. The pioneer and leader
in the technology to monitor and manage airway inflammation, Aerocrine markets
NIOX MINO® and NIOX® Flex. Both products enable the fast and reliable
measurement of airway inflammation and may thus play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm
Stock Exchange on 15 June 2007.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act. The information was submitted for publication at
8:00 am on April the 7th 2010.